These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 10174288)
1. International forum: Europe. Buffy-coat-derived platelet concentrates: Swedish experience. Högman CF; Berséus O; Eriksson L; Gulliksson H Transfus Sci; 1997 Mar; 18(1):3-13. PubMed ID: 10174288 [TBL] [Abstract][Full Text] [Related]
2. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Klüter H; Dörges L; Maass E; Wagner T; Bartels H; Kirchner H Ann Hematol; 1996 Aug; 73(2):85-9. PubMed ID: 8774617 [TBL] [Abstract][Full Text] [Related]
3. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates. Singh S; Shams Hakimi C; Jeppsson A; Hesse C Transfus Apher Sci; 2017 Dec; 56(6):870-874. PubMed ID: 29126740 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis. Eriksson L; Kristensen J; Olsson K; Bring J; Högman CF Vox Sang; 1996; 70(2):69-75. PubMed ID: 8801766 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Bertolini F; Rebulla P; Riccardi D; Cortellaro M; Ranzi ML; Sirchia G Transfusion; 1989 Sep; 29(7):605-9. PubMed ID: 2773027 [TBL] [Abstract][Full Text] [Related]
6. A system for the supply of platelets suspended in a storage medium including buffy-coat-derived platelet concentrates in combination with "split" apheresis platelets. Gulliksson H; Larsson S; Shanwell A; Pedajas I; Joie M; Flament J Transfus Sci; 1997 Mar; 18(1):33-40. PubMed ID: 10174289 [TBL] [Abstract][Full Text] [Related]
7. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies. Eriksson L; Shanwell A; Gulliksson H; Högman CF; Svensson LA; Kristensen J; Berg B Vox Sang; 1993; 64(3):133-8. PubMed ID: 8484245 [TBL] [Abstract][Full Text] [Related]
8. Relationship of the time of storage and transfusion reactions to platelet concentrates from buffy coats. Riccardi D; Raspollini E; Rebulla P; Pappalettera M; Marangoni F; Greppi N; Sirchia G Transfusion; 1997 May; 37(5):528-30. PubMed ID: 9149780 [TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation. Fernández-Muñoz H; Plaza EM; Rivera-Caravaca JM; Candela MJ; Romera M; De Arriba F; Lozano ML; Vicente V; Heras I; Castilla-Llorente C; Rivera J Hematology; 2018 Oct; 23(9):712-718. PubMed ID: 29582705 [TBL] [Abstract][Full Text] [Related]
10. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Oksanen K; Ebeling F; Kekomäki R; Elonen E; Sahlstedt L; Volin L; Myllylä G Vox Sang; 1994; 67(4):356-61. PubMed ID: 7701806 [TBL] [Abstract][Full Text] [Related]
11. Transfusion of platelet concentrates--clinical evaluation of two preparations. Strindberg J; Berlin G Eur J Haematol; 1996 Oct; 57(4):307-11. PubMed ID: 8982294 [TBL] [Abstract][Full Text] [Related]
12. Quality assessment of platelet concentrates prepared by platelet-rich plasma, buffy-coat, and apheresis methods in a tertiary care hospital in South India: A cross-sectional study. Toora E; Kulkarni RG; Manivannan P; Sastry AS; Basavarajegowda A; Sahoo D Asian J Transfus Sci; 2023; 17(2):239-245. PubMed ID: 38274963 [TBL] [Abstract][Full Text] [Related]
13. Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Bertolini F; Rebulla P; Porretti L; Murphy S Transfusion; 1992 Jan; 32(1):9-16. PubMed ID: 1731448 [TBL] [Abstract][Full Text] [Related]
14. Quality assessment of buffy-coat-derived leucodepleted platelet concentrates in PAS-plasma, prepared by the OrbiSac or TACSI automated system. Plaza EM; Céspedes P; Fernández H; Sánchez-Guiu MI; Egea JM; Vicente V; Lozano ML; Rivera J Vox Sang; 2014 Jan; 106(1):38-44. PubMed ID: 23888911 [TBL] [Abstract][Full Text] [Related]
15. Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Böck M; Rahrig S; Kunz D; Lutze G; Heim MU Transfus Med; 2002 Oct; 12(5):317-24. PubMed ID: 12383338 [TBL] [Abstract][Full Text] [Related]
16. In vitro variables of buffy coat-derived platelet concentrates with residual plasma of down to 10% are stably maintained in new-generation platelet additive solutions. Gravemann U; Volgmann T; Min K; Philipp R; Lambrecht B; Müller TH; Seltsam A Transfusion; 2015 Jul; 55(7):1700-9. PubMed ID: 25677807 [TBL] [Abstract][Full Text] [Related]
17. Pooled platelet concentrates: an alternative to single donor apheresis platelets? Pietersz RN Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340 [TBL] [Abstract][Full Text] [Related]
18. Use of random versus apheresis platelet concentrates. Andreu G; Vasse J; Sandid I; Tardivel R; Semana G Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401 [TBL] [Abstract][Full Text] [Related]
19. Preparation and pathogen inactivation of double dose buffy coat platelet products using the INTERCEPT blood system. Abedi MR; Doverud AC J Vis Exp; 2012 Dec; (70):e4414. PubMed ID: 23242463 [TBL] [Abstract][Full Text] [Related]
20. Differences in levels of platelet-derived microparticles in platelet components prepared using the platelet rich plasma, buffy coat, and apheresis procedures. Noulsri E; Udomwinijsilp P; Lerdwana S; Chongkolwatana V; Permpikul P Transfus Apher Sci; 2017 Apr; 56(2):135-140. PubMed ID: 28029568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]